Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Trocio

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|December 15, 2015
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulantsSteve Deitelzweig, Amanda Bruno, Jeffrey Trocio, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2017
Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United StatesSteven B Deitelzweig, Michael Evans, Jeffrey Trocio, et al.
Journal of Medical Economics|October 20, 2017
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health planAlpesh Amin, Allison Keshishian, Lien Vo, et al.
Plos One|April 13, 2018
Estimated prevalence of undiagnosed atrial fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
Health and Quality of Life Outcomes|April 25, 2012
Linguistic validation of translation of the Self-Assessment Goal Achievement (SAGA) questionnaire from EnglishElisabeth Piault, Sameepa Doshi, Barbara A Brandt, et al.
BMC Cardiovascular Disorders|June 15, 2019
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense populationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
Journal of Medical Economics|June 13, 2017
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world settingJay Lin, Jeffrey Trocio, Kiran Gupta, et al.
Current Medical Research and Opinion|August 30, 2017
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patientsSteven Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial FibrillationSteven Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Physician and Patient Preferences for Nonvalvular Atrial Fibrillation TherapiesJason Shafrin, Amanda Bruno, Joanna P MacEwan, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|December 15, 2015
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulantsSteve Deitelzweig, Amanda Bruno, Jeffrey Trocio, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|February 1, 2017
Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United StatesSteven B Deitelzweig, Michael Evans, Jeffrey Trocio, et al.
Journal of Medical Economics|October 20, 2017
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health planAlpesh Amin, Allison Keshishian, Lien Vo, et al.
Plos One|April 13, 2018
Estimated prevalence of undiagnosed atrial fibrillation in the United StatesMintu P Turakhia, Jason Shafrin, Katalin Bognar, et al.
Health and Quality of Life Outcomes|April 25, 2012
Linguistic validation of translation of the Self-Assessment Goal Achievement (SAGA) questionnaire from EnglishElisabeth Piault, Sameepa Doshi, Barbara A Brandt, et al.
BMC Cardiovascular Disorders|June 15, 2019
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense populationKiran Gupta, Jeffrey Trocio, Allison Keshishian, et al.
Journal of Medical Economics|June 13, 2017
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world settingJay Lin, Jeffrey Trocio, Kiran Gupta, et al.
Current Medical Research and Opinion|August 30, 2017
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patientsSteven Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial FibrillationSteven Deitelzweig, Xuemei Luo, Kiran Gupta, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Physician and Patient Preferences for Nonvalvular Atrial Fibrillation TherapiesJason Shafrin, Amanda Bruno, Joanna P MacEwan, et al.
Pageof 4